Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	The primary end-point will be to evaluate the efficacy of low-dose pulmonary irradiation using a Linear accelerator as an adjunctive treatment for patients with COVID-19 pneumonia by improving the PaO2-FiO2 by 20% measured 48-72h after treatment with respect to baseline pre-irradiation measurement.Timepoint: 48-72h after treatment	The primary end-point will be to evaluate the efficacy of low-dose pulmonary irradiation using a Linear accelerator as an adjunctive treatment for patients with COVID-19 pneumonia by improving the PaO2-FiO2 by 20% measured 48-72h after treatment with respect to baseline pre-irradiation measurement.Timepoint: 48-72h after treatment
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Sept. 8, 2021, 1:30 a.m.	oms	The primary end-point will be to evaluate the efficacy of low-dose pulmonary irradiation using a Linear accelerator as an adjunctive treatment for patients with COVID-19 pneumonia by improving the PaO2-FiO2 by 20% measured 48-72h after treatment with respect to baseline pre-irradiation measurement.Timepoint: 48-72h after treatment	The primary end-point will be to evaluate the efficacy of low-dose pulmonary irradiation using a Linear accelerator as an adjunctive treatment for patients with COVID-19 pneumonia by improving the PaO2-FiO2 by 20% measured 48-72h after treatment with respect to baseline pre-irradiation measurement.Timepoint: 48-72h after treatment